Company:  CEL SCI CORP (CVM)
Form Type:  4
Filing Date:  6/13/2018 
CIK:  0000725363 
Address:  8229 BOONE BLVD .
SUITE 802
 
City, State, Zip:  VIENNA, Virginia 22182 
Telephone:  (703) 506-9460 
Fiscal Year:  09/30 
Last Trade
Last Trade: 
$3.83  
Change: 
0.28 (7.89%)  
Trade Time: 
Sep 21  
Market Cap: 
$104.76M
Trade CVM now with

© 2018  
Description of Business
CEL-SCI is focused on finding the best way to activate the immune system to fight cancer and infectious diseases. Its lead investigational therapy Multikine® (Leukocyte Interleukin, Injection) is currently in a pivotal Phase 3 clinical trial involving head and neck cancer, for which CEL-SCI has received Orphan Drug Status from the U.S. FDA. If the primary endpoint of this global study is achieved, the results will be used to support applications to regulatory agencies around the world for worldwide commercial marketing approvals as a first line cancer therapy. CEL-SCI's immune therapy, Multikine, is being used in a different way than immune therapy is usually used. It is given before any other therapy has been administered because that is when the immune system is thought to be strongest. It is also administered locally to treat tumors or infections.
Register and access this filing in:     
  FORM 4
    NAME AND TITLE
    NON DERIVATIVE SECURITIES
    DERIVATIVE SECURITIES
    EXPLANATIONS AND REMARKS
    REPORTING OWNERS
    SIGNATURES